AACR 2023 | LCMC3: adjuvant and neoadjuvant atezolizumab in early-stage NCSLC
David Carbone, MD, PhD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses findings from the single arm, Phase II LCMC3 study (NCT02927301) of atezolizumab in the adjuvant and neoadjuvant setting in patients with early stage non-small cell lung cancer (NSCLC). The 3 year survival and overall survival rates and were promising, and no new safety concerns were reported. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So, it was a single arm Phase II, but it was a very large one. It was 180 patients, which is larger than any of the NADIM trials or the nivo monotherapy trials. And what we found was in a three-year survival analysis, that the overall survival was really very excellent with stage three patients having a survival of greater than 80% at three years, similar to those with stages one and two. But in this presentation, we also looked at a multivariable analysis examining the impact of adjuvant atezolizumab or adjuvant chemotherapy in a setting where they only got neoadjuvant atezolizumab alone, which is different from many of the studies that are going on now...
So, it was a single arm Phase II, but it was a very large one. It was 180 patients, which is larger than any of the NADIM trials or the nivo monotherapy trials. And what we found was in a three-year survival analysis, that the overall survival was really very excellent with stage three patients having a survival of greater than 80% at three years, similar to those with stages one and two. But in this presentation, we also looked at a multivariable analysis examining the impact of adjuvant atezolizumab or adjuvant chemotherapy in a setting where they only got neoadjuvant atezolizumab alone, which is different from many of the studies that are going on now. And it turns out about half of the patients elected to get adjuvant atezolizumab and half didn’t. And we did a multivariable analysis and it interestingly showed that PD-L1 had a trend toward influencing outcome, but the confidence intervals crossed one. But what did show a statistically significant impact in multivariate analysis was both adjuvant chemo and adjuvant atezolizumab, with hazard ratios in the 0.4 range and confidence intervals not crossing one.
Read more...
